Hormonal replacement therapy by patientsafter treatment for gynecological cancer

Czech version

Authors: P. Havelka; V. Kalist; Z. Adamík
Authors‘ workplace: Gynekologicko-porodnické oddělení, Krajská nemocnice T. Bati, a. s., Zlín, přednosta prim. MUDr. Z. Adamík, Ph. D.
Published in: Ceska Gynekol 2014; 79(3): 179-185

Overview

Objective:
The most of gynecological cancers are diagnosed in postmenopausal period. There are, however, part of the premenopausal women which occurs to develop vegetative problems after medical procedures. The aim of the study is to provide an overview of the current status and views on hormone replacement therapy in women after treatment for gynecologic malignancy. Subject: Systematic review. Methods: Current literature review. Conclusion: The available literature sources don´t show that hormone replacement therapy for premenopausal women worsens the prognosis of the underlying disease after treatment of gynecological cancer. The limiting factor in most of the works are small groups of patients and the low stage of disease at enrollment (especially for endometrial cancer). Even though no study has shown worsening prognosis or shorter disease free interval. However, it is necessary to proceed individually for each patient with an evaluation of the current status and potential benefits that this treatment can get. Keywords: endometrial cancer, ovarian cancer, cevical carcinoma, hormonal replacement therapy

Sources

1. Anderson, GL., Judd, HL., Kaunitz, AM., et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures. JAMA, 2003, 290, p. 1739–1748.

2. Auborn, KJ., Woodworth, C., DiPaolo, JA., et al. The interaction between HPV infection and estrogen metabolism in cervical carcinogenesis. Int J Cancer, 1991, 49, p. 867–869.

3. Baker, DP. Estrogen-replacement therapy in patients with previous endometrial carcinoma. Compr Ther, 1990, 16, p. 28–35.

4. Barakat, RR., Bundy, BN., Spirtos, NM., et al. Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study. J Clin Oncol, 2006, 24, p. 587–592.

5. Beral, V., Bull, D., Reeves, G., et al. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet, 2005, 395, p. 1543–1541.

6. Callahan, MJ., Crum, CP., Medeiros, F., et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol, 2007, 25, p. 3985–3990.

7. Cibula, D. Onkogynekologie. Praha: Grada Publishing, 2009, s. 465.

8. Cibula, D., Widschwendter, M., Zikan, M., et al. Underlying mechanisms of ovarian cancer risk reduction after tubal ligation. Acta Obstet Gynecol Scand, 2011, 90, p. 559–563.

9. Coughlin, SS., Giustozzi, A., Smith, SJ., et al. A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancer. J Clin Epidemiol, 2000, 53, p. 367–375.

10. Creasman, WT., Henderson, D., Hinshaw, W., et al. Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet Gynecol, 1986, 67, p. 326–330.

11. Eeles, RA., Ran, S., Witshaw, E., et al. Hormone replacement therapy and survival after surgery for ovarian cancer. BMJ, 1991, 302, p. 259–262.

12. Fathalla, MF. Incessant ovulation – a factor in ovarian neoplasia? Lancet, 1971, 2, p. 163.

13. Garg, PP., Kerlikowscke, K., Subac, L., et al. Hormone replacement therapy and risk of epithelian ovarian carcinoma: a meta-analysis. Obstet Gynecol, 1998, 92, p. 472–479.

14. Grady, D., Gebretsadik, T., Kerlikowske, K., et al. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol, 1995, 85, p. 304–313.

15. Greiser, CM., Greiser, EM., Doren, M., et al. Menopausal hormone therapy and risk of ovarian cancer: systematic review and meta-analysis. Hum Reprod Update, 2007, 13, p. 453–463.

16. Guidozzi, F., Daponte, A. Estrogen replacement therapy for ovarian carcinoma survivors: A randomized controlled trial. Cancer, 1999, 86, p. 1013–1018.

17. Chapman, JA., DiSaia, PJ., Osnann, K., et al. Estrogen replacement in surgical stage I and II endometrial cancer survivors. Am J Obstet Gynecol, 1996, 175, p. 1195–1200.

18. Lacey, JV., Brintol, LA., Barnes, WA., et al. Use of hormone replacement therapy and adenocarcinomas and squamous cell carcinomas of the uterine cervix. Gynecol Oncol, 2000, 77, p. 149–154.

19. Lee, RB., Burke, TW., Park, RC. Estrogen replacement therapy following treatment for stage I endometrial carcinoma. Gynecol Oncol, 1990, 36, p. 189–191.

20. Li, J., Abushahin, N., Pang, S., et al. Tubal origin of „ovarian“ low-grade serous carcinoma. Mod Pathol, 2011, 24, p. 1488–1499.

21. Mascarenhas, CH., Lambe, M., Bellocco, R., et al. Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival. In J Cancer, 2006, 119, p. 2907–2915.

22. Novotvary. Praha: ÚZIS, 2009.

23. Pearce, CL., Chung, K., Pik,e MC., et al. Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin. Cancer, 2009, 115, p. 531–539.

24. Ploch, E. Hormonal replacement therapy in patients after cervical cancer treatment. Gynecol Oncol, 1987, 26, p. 169–177.

25. Rossouw, JE., Anderson, GL., Prentice, RL., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women‘s Health Initiative randomized controlled trial. JAMA, 2002, 288, p. 321–323.

26. Smith, JS., Green, J., Berrington de Gonzales, A., et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet, 2003, 361, p. 1159–1167.

27. Suriano, KS., McHale, M., McLaren, CE., et al. Estrogen replacement therapy in endometrial cancer patients: a matched control study. Obstet Gynecol, 2001, 97, p. 555–560.

28. Ursic-Vrscaj, M., Bebar, S., Zakelj, MP. Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival. Menopause, 2001, 8, p. 70–75.